Abstract
Protein SUMOylation regulates the activity of a wide range of cellular substrates, and the identification of small ubiquitin-related modifier (SUMO)-modified sites is often required to understand how this modification affects protein function. However, the site-specific identification of modified lysine residues by mass spectrometry (MS) remains challenging because of the dynamic nature of this modification, its low stoichiometry and the relatively large SUMO remnant left on peptide backbones after tryptic digestion. Here we report a versatile method to identify sites and to profile the extent of modification on recombinant proteins from in vitro SUMOylation assays. We define the steps required for sample preparation, and we describe how to perform proper controls and conduct the liquid chromatography-MS (LC-MS) and bioinformatics analyses. Native protein substrates can be used for the assay, although we recommend the use of His-tagged proteins to facilitate removal of contaminants. The procedure was developed for human SUMO paralogs, and it requires <2 d for completion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bettermann, K., Benesch, M., Weis, S. & Haybaeck, J. SUMOylation in carcinogenesis. Cancer Lett. 316, 113–125 (2012).
Dou, H., Huang, C., Van Nguyen, T., Lu, L.S. & Yeh, E.T. SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett. 585, 2891–2896 (2011).
Meulmeester, E. & Melchior, F. Cell biology: SUMO. Nature 452, 709–711 (2008).
Saitoh, H. & Hinchey, J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252–6258 (2000).
Tatham, M.H., Matic, I., Mann, M. & Hay, R.T. Comparative proteomic analysis identifies a role for SUMO in protein quality control. Sci. Signal. 4, rs4 (2011).
Rodriguez, M.S., Dargemont, C. & Hay, R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654–12659 (2001).
Hay, R.T. SUMO: a history of modification. Mol. Cell 18, 1–12 (2005).
Tatham, M.H. et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276, 35368–35374 (2001).
Matic, I. et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high-accuracy mass spectrometry and an in vitro to in vivo strategy. Mol. Cell. Proteomics 7, 132–144 (2008).
Galisson, F. et al. A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells. Mol. Cell. Proteomics 10, M110.004796 (2011).
Geiss-Friedlander, R. & Melchior, F. Concepts in SUMOylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947–956 (2007).
Gareau, J.R. & Lima, C.D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861–871 (2010).
Sampson, D.A., Wang, M. & Matunis, M.J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664–21669 (2001).
Duan, X., Trent, J.O. & Ye, H. Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design. Anticancer Agents Med. Chem. 9, 51–54 (2009).
Hershko, A., Ciechanover, A. & Varshavsky, A. Basic Medical Research Award. The ubiquitin system. Nat. Med. 6, 1073–1081 (2000).
Lamoliatte, F. et al. Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling. Nat. Commun. 5, 5409 (2014).
Flotho, A. et al. Recombinant reconstitution of SUMOylation reactions in vitro. Methods Mol. Biol. 832, 93–110 (2012).
Weber, A.R., Schuermann, D. & Schar, P. Versatile recombinant SUMOylation system for the production of SUMO-modified protein. PLoS ONE 9, e102157 (2014).
Werner, A., Moutty, M.C., Moller, U. & Melchior, F. Performing in vitro SUMOylation reactions using recombinant enzymes. Methods Mol. Biol. 497, 187–199 (2009).
Knipscheer, P. et al. Ubc9 SUMOylation regulates SUMO target discrimination. Mol. Cell 31, 371–382 (2008).
Sarge, K.D. & Park-Sarge, O.K. Detection of proteins sumoylated in vivo and in vitro. Methods Mol. Biol. 590, 265–277 (2009).
Hendriks, I.A. et al. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat. Struct. Mol. Biol. 21, 927–936 (2014).
Impens, F., Radoshevich, L., Cossart, P. & Ribet, D. Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc. Natl. Acad. Sci. USA 111, 12432–12437 (2014).
Tammsalu, T. et al. Proteome-wide identification of SUMO2 modification sites. Sci. Signal. 7, rs2 (2014).
Barysch, S.V., Dittner, C., Flotho, A., Becker, J. & Melchior, F. Identification and analysis of endogenous SUMO1 and SUMO2/3 targets in mammalian cells and tissues using monoclonal antibodies. Nat. Protoc. 9, 896–909 (2014).
Becker, J. et al. Detecting endogenous SUMO targets in mammalian cells and tissues. Nat. Struct. Mol. Biol. 20, 525–531 (2013).
Hsiao, H.H., Meulmeester, E., Frank, B.T., Melchior, F. & Urlaub, H. 'ChopNSpice,' a mass spectrometric approach that allows identification of endogenous small ubiquitin-like modifier-conjugated peptides. Mol. Cell. Proteomics 8, 2664–2675 (2009).
Pedrioli, P.G. et al. Automated identification of SUMOylation sites using mass spectrometry and SUMmOn pattern recognition software. Nat. Methods 3, 533–539 (2006).
Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513–2526 (2014).
Lamoliatte, F. et al. Targeted identification of SUMOylation sites in human proteins using affinity enrichment and paralog-specific reporter ions. Mol. Cell. Proteomics 12, 2536–2550 (2013).
Wisniewski, J.R., Hein, M.Y., Cox, J. & Mann, M. A 'Proteomic Ruler' for protein copy number and concentration estimation without spike-in standards. Mol. Cell. Proteomics 13, 3497–3506 (2014).
Beck, M. et al. The quantitative proteome of a human cell line. Mol. Syst. Biol. 7, 549 (2011).
Acknowledgements
This work was funded by the Natural Sciences and Engineering Research Council (NSERC) and Genome Canada. F.P.M. is the recipient of postdoctoral fellowship from NSERC. We thank F. Lamoliatte for technical assistance with the MS analysis, and A. Verreault for PCNA and CBX1 recombinant proteins and for the plasmid encoding CHAF1A. The Institute for Research in Immunology and Cancer (IRIC, Université de Montréal, Montréal, Québec, Canada) receives infrastructure support from IRICoR, the Canadian Foundation for Innovation and the Fonds de Recherche du Québec–Santé (FRQS).
Author information
Authors and Affiliations
Contributions
F.P.M. and C.D.A. carried out molecular biology and blotting experiments with the SUMO3 variant. F.P.M. prepared and optimized the current protocol and performed the LC-MS/MS experiments and analyzed the data. F.P.M. and P.T. wrote the manuscript. P.T. developed the concept and managed the project.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Comparison of in vitro SUMOylation assay for RanGAP using native SUMO3 and SUMO3 (NQTGG) mutant.
(a) Western blot showing the SUMOylation of RanGAP with native and mutant SUMO3 proteins with and without ATP. MS/MS spectra of the Lys-524 SUMOylated RanGAP peptide with (b) SUMO3 (NQTGG) mutant and (c) native SUMO3 proteins. A series of b- and y-type fragment ions corresponding to the tryptic peptide with a modified K-198 residue is observed when using the SUMO3 mutant and facilitated its identification by the search engine Andromeda. In contrast, limited fragmentation of the peptide backbone is noted for the native SUMO3, and the corresponding MS/MS spectrum could not be identified by Andromeda.
Supplementary information
Supplementary Text and Figures
Supplementary Figure 1 and Supplementary Table 1 (PDF 475 kb)
Rights and permissions
About this article
Cite this article
McManus, F., Altamirano, C. & Thibault, P. In vitro assay to determine SUMOylation sites on protein substrates. Nat Protoc 11, 387–397 (2016). https://doi.org/10.1038/nprot.2016.023
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2016.023
This article is cited by
-
Proteomic strategies for characterizing ubiquitin-like modifications
Nature Reviews Methods Primers (2021)
-
Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders
Journal of Biosciences (2020)
-
Quantitative SUMO proteomics reveals the modulation of several PML nuclear body associated proteins and an anti-senescence function of UBC9
Scientific Reports (2018)
-
Identification of cross talk between SUMOylation and ubiquitylation using a sequential peptide immunopurification approach
Nature Protocols (2017)
-
An improved method for identifying SUMOylation sites of viral proteins
Virologica Sinica (2017)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.